Trulieve Cannabis Corp.
TRLV NYSE· Medicinal Chemicals & Botanical Products
Last close · Oct 26, 2026
$10.82
KIRA · Stoqly’s AI analyst, in plain words
- Trulieve Cannabis Corp. had $1.2B of revenue in fiscal 2025, down 0.4% on the year before. Over five years, revenue changed +17.8% a year on average.
- Its operating margin was 12.1%, up 3.9 pts: of every 100 in sales, about 12 is left after running the business.
- Trulieve Cannabis Corp. lost $122M in fiscal 2025.
- Free cash flow was $229M in fiscal 2025, 19.4% of revenue.
- Trulieve Cannabis Corp. has $44.0M more cash than debt.
Market cap
$2.1B
P/E
—
Revenue
$1.2B
Net income
−$122M
Free cash flow
$229M
Operating margin
12.1%
Trulieve Cannabis Corp. in 30 seconds · fiscal 2025
Are sales growing?
−0.4%
No. Sales fell 0.4% last year.
Does it make a profit?
−10.3%
No. It lost money last year.
Does profit turn into cash?
19.4%
Yes. 19.4% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Trulieve Cannabis Corp. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Trulieve Cannabis Corp.
- CIK
- 0001754195
Trulieve Cannabis Corp. · TRLV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $932M | $1.2B | $1.1B | $1.2B | $1.2B |
| Revenue growth | 78.7% | 30.7% | −7.3% | 5.1% | −0.4% |
| Gross margin | 60.8% | 56.6% | 52.1% | 60.3% | 60.2% |
| Operating margin | 21.9% | 4.1% | −19.6% | 8.2% | 12.1% |
| Net income | $17.4M | −$253M | −$533M | −$161M | −$122M |
| Net margin | 1.9% | −20.7% | −47.2% | −13.5% | −10.3% |
| Diluted EPS | $0.21 | −$0.95 | −$2.28 | −$0.79 | −$0.58 |
| Cash | |||||
| Cash from operations | $12.9M | $23.1M | $202M | $271M | $273M |
| Capital expenditure | $276M | $165M | $40.2M | $123M | $44.2M |
| Free cash flow | −$263M | −$142M | $162M | $149M | $229M |
| FCF margin | −28.2% | −11.6% | 14.3% | 12.5% | 19.4% |
| Share count change | 24.0% | 28.1% | 0.5% | 0.5% | 0.7% |
| Debt and strength | |||||
| Cash and short-term investments | $227M | $207M | $201M | $299M | $256M |
| Debt incl. finance leases | $534M | $626M | $433M | $442M | $212M |
| Loans, net | — | $12.7M | $13.7M | — | — |
| Shareholders' equity | $2.1B | $1.9B | $1.4B | $1.2B | $1.1B |
| Net debt / EBITDA | 1.2x | 2.5x | — | 0.7x | −0.2x |
| Current ratio | 3.1x | 2.8x | 4.2x | 4.4x | 4.4x |
| Interest coverage | 7.0x | 0.7x | −2.7x | 1.6x | 2.3x |
| Returns and quality | |||||
| Return on capital | 5.6% | 1.8% | −11.1% | 4.8% | 9.1% |
| Return on equity | 1.3% | −12.4% | −32.0% | −12.1% | −10.2% |
| Return on tangible equity | 6.8% | −162.5% | −7,008.1% | — | — |
| Piotroski F-score | 2 | 3 | 5 | 6 | 6 |
| Altman Z'' | 3.0 | 2.1 | 0.7 | 1.2 | 1.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$14.7M
1 insider
Of sales under plans
100%
$14.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Trulieve Cannabis Corp. · TRLV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.82 a share, the company is worth $2.1B.
Source: SEC EDGAR XBRL filings (CIK 0001754195). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.